Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 20

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 20
---
 of our Ordinary Shares.                                           |

| • |     | An active, liquid trading market for our Ordinary Shares may not be maintained. |

| • |     | Our executive officers, directors and principal shareholders, if they choose to act together, will have the                                                                                
 ability to control or significantly influence all matters submitted to shareholders for approval. Furthermore, some of our current directors were appointed by our principal shareholders. |

| • |     | We do not currently intend to pay dividends on our securities, and, consequently, the ability to achieve a            
 return on investment in our Ordinary Shares will depend on appreciation, if any, in the price of our Ordinary Shares. |

| • |     | Sales of a substantial number of our Ordinary Shares by our existing shareholders in the public market could 
 cause the price of our Ordinary Shares to fall.                                                              |

| • |     | We are an emerging growth company and smaller reporting company, and the reduced disclosure requirements                           
 applicable to emerging growth companies and smaller reporting companies may make our Ordinary Shares less attractive to investors. |

12

| • |     | As a foreign private issuer, we are not subject to some U.S. securities law disclosure requirements that apply 
 to a U.S. domestic issuer, which may limit the information publicly available to our shareholders.             |

| • |     | As a foreign private issuer, we are permitted to adopt some home country practices in relation to corporate                                                                                                                                             
 governance matters that differ significantly from the Nasdaq corporate governance listing standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully with corporate governance listing standards. |

| • |     | Under our amended and restated memorandum and articles of association, investors do not have the same rights 
 with respect to shareholder meetings and voting that shareholders of some U.S. corporations have.            |

| • |     | We may lose our foreign private issuer status in the future, which could result in significant additional 
 costs and expenses.                                                                                       |

| • |     | Fluctuations in currency exchange rates may have a material adverse effect on our results of operations and 
 the value of any investment in our Ordinary Shares.                                                         |

| • |     | Investors may not receive distributions on our Ordinary Shares or any value for them if such distribution is                                   
 illegal or impractical or if any required government approval cannot be obtained in order to make such distribution available to any investor. |

| • |     | Investors’ right to participate in any future rights offerings may be limited, which may cause dilution